Medical Research Council-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.
Front Immunol. 2020 Oct 6;11:573662. doi: 10.3389/fimmu.2020.573662. eCollection 2020.
Bearing a strong resemblance to the phenotypic and functional remodeling of the immune system that occurs during aging (termed immunesenescence), the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 2019 (COVID-19), is characterized by an expansion of inflammatory monocytes, functional exhaustion of lymphocytes, dysregulated myeloid responses and the presence of highly activated senescent T cells. Alongside advanced age, male gender and pre-existing co-morbidities [e.g., obesity and type 2 diabetes (T2D)] are emerging as significant risk factors for COVID-19. Interestingly, immunesenescence is more profound in males when compared to females, whilst accelerated aging of the immune system, termed premature immunesenescence, has been described in obese subjects and T2D patients. Thus, as three distinct demographic groups with an increased susceptibility to COVID-19 share a common immune profile, Here, by focussing on three key aspects of an immune response, namely pathogen recognition, elimination and resolution, we address this question by discussing how immunesenescence may weaken or exacerbate the immune response to SARS-CoV-2. We also highlight how aspects of immunesenescence could render potential COVID-19 treatments less effective in older adults and draw attention to certain therapeutic options, which by reversing or circumventing certain features of immunesenescence may prove to be beneficial for the treatment of groups at high risk of severe COVID-19.
与衰老过程中发生的免疫系统表型和功能重塑(称为免疫衰老)非常相似,严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2),即 2019 年冠状病毒病(COVID-19)的病原体,引发的免疫反应表现为炎症性单核细胞的扩增、淋巴细胞功能衰竭、髓样细胞反应失调以及高度激活的衰老 T 细胞的存在。除了高龄以外,男性和先前存在的合并症(如肥胖和 2 型糖尿病(T2D))也成为 COVID-19 的显著危险因素。有趣的是,与女性相比,男性的免疫衰老更为明显,而肥胖个体和 T2D 患者的免疫系统加速衰老,被称为过早的免疫衰老。因此,由于三个具有更高 COVID-19 易感性的不同人群具有共同的免疫特征,在这里,我们通过关注免疫反应的三个关键方面,即病原体识别、清除和解决,通过讨论免疫衰老如何削弱或加剧对 SARS-CoV-2 的免疫反应来回答这个问题。我们还强调了免疫衰老的哪些方面可能会使潜在的 COVID-19 治疗在老年人中效果降低,并提请注意某些治疗选择,这些选择通过逆转或规避免疫衰老的某些特征,可能对高危 COVID-19 人群的治疗有益。